The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

The present invention relates to compositions comprising immunomodulatory polynucleotides as therapeutics, such as for immunotherapy. Further, the present invention relates to the use of the compositions in the treatment of diseases such as cancers.

Provided are compositions and methods for transport, monitoring the transport, and controlled release of active agents. The compositions comprise surface functionalized iron oxide nanoparticles. The iron oxide nanoparticles are surface functionalized with cucurbitril[7] macrocycles. The cavity formed by the CB[7] macrocycles can be used for storage and transport of active agents. The active agents may be imaging agents or may be therapeutic agents which can be released by applying an alternating magnetic field at desired locations.

Provided are compositions and methods for transport, monitoring the transport, and controlled release of active agents. The compositions comprise surface functionalized iron oxide nanoparticles. The iron oxide nanoparticles are surface functionalized with cucurbitril[7] macrocycles. The cavity formed by the CB[7] macrocycles can be used for storage and transport of active agents. The active agents may be imaging agents or may be therapeutic agents which can be released by applying an alternating magnetic field at desired locations.

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.

A multivesicular liposome composition includes a plurality of multivesicular liposomes. Each multivesicular liposome includes a carrier liposome particle including carrier phospholipid bilayer and having an average diameter less than 1 micron; and at least one sub-chamber liposome nanoparticle including a sub-chamber liposome nanoparticle bilayer and having an average diameter less than about 50 nm. The carrier liposome particle encapsulates the at least one sub-chamber liposome nanoparticle. Characteristically, tail groups of the carrier liposome phospholipids are larger than tail groups phospholipids of the at least one sub-chamber liposome nanoparticle.

Compositions comprising an antigen, a carbohydrate, and a metabolizable oil, methods of administering such compositions to a subject, methods of making such compounds, and related compositions, methods, and uses.

Compositions comprising an antigen, a carbohydrate, and a metabolizable oil, methods of administering such compositions to a subject, methods of making such compounds, and related compositions, methods, and uses.